Mode
Text Size
Log in / Sign up

Piranha morcellation device shows higher efficiency and lower bladder injury risk than VersaCutDifferent prostate morcellation tools show varying efficiency and safety levels

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider Piranha over VersaCut for higher morcellation efficiency and lower bladder injury risk in large prostates.

This meta-analysis evaluated the performance and safety of various prostate morcellation devices, including Piranha, VersaCut, DrillCut, MultiCut, and Cyber Blade, in patients undergoing prostate enucleation for benign prostatic hyperplasia (BPH). The total sample size across the analyzed studies was 5,980 patients. The study aimed to compare these devices based on morcellation efficiency, intraoperative complications, device malfunction, and cost.

The primary outcome measured was morcellation efficiency, expressed in grams per minute (g/min). The unadjusted weighted mean morcellation efficiency for the specific devices was recorded as follows: Piranha at 7.80 g/min (95% CI 6.26-9.34), VersaCut at 4.70 g/min (95% CI 3.61-5.79), DrillCut at 5.90 g/min (95% CI 3.16-8.64), and MultiCut at 9.59 g/min (95% CI 4.78-14.39).

When comparing the two primary devices of interest, the VersaCut was found to be significantly less efficient than the Piranha in terms of volume-adjusted morcellation efficiency. The difference was -2.75 g/min (95% CI -4.58 to -0.92; P = 0.003). This finding was even more pronounced in larger prostates (greater than 70 mL), where the VersaCut was significantly less efficient than the Piranha by -4.34 g/min.

Regarding safety and complications, the study specifically analyzed the risk of bladder mucosal injury. The results indicated a significantly higher risk with the VersaCut compared to the Piranha, with an effect size of 3.22 (95% CI 1.81-5.71). While bladder mucosal injury was identified as the most frequently reported complication across all devices, it was noted as relatively rare across the entire cohort.

These results suggest a clear distinction between oscillating blade systems (Piranha) and reciprocating blade devices (VersaCut). The Piranha system demonstrated higher morcellation efficiency and a more favorable safety profile, particularly in cases involving larger prostates. These findings provide evidence for surgeons choosing between these specific technologies during the enucleation process.

Methodological limitations were not reported. However, the distinction between the two device types is clear in the results. The clinical implications suggest that for patients with larger prostates, the Piranha system may offer a more efficient and safer surgical experience. Questions remain regarding the long-term clinical outcomes and the specific costs and malfunction rates of each device, as these were not detailed in the primary results provided.

How this fits prior evidence

How this fits prior evidence: This finding addresses a gap in surgical technique selection for benign prostatic hyperplasia. While previous evidence has focused on medical management, such as alpha-adrenergic receptor antagonists to improve trial without catheter success by 24.5%, and the risks of specific implants like the UroLume endoprosthesis, this study provides specific comparative data on surgical morcellation tools. It specifically highlights the superiority of oscillating blades over reciprocating blades in large prostates.

Men with an enlarged prostate, a condition known as benign prostatic hyperplasia, often require surgery to improve urinary function. During these procedures, surgeons use specialized tools to break up and remove prostate tissue. This process is called morcellation. Because different types of morcellation devices are available, it is important to understand how these tools perform and how they affect patient safety during the operation.

Researchers conducted a meta-analysis to compare several different morcellation devices, including the Piranha, VersaCut, DrillCut, MultiCut, and Cyber Blade. The study looked at data from nearly 6,000 patients who underwent prostate enucleation. The primary goal was to measure how efficiently these tools could break down tissue and to identify any differences in complications or malfunctions between the various models.

The results showed that different devices performed differently. For example, the Piranha device showed a higher average efficiency of 7.80 grams per minute, while the VersaCut device showed a lower average of 4.70 grams per minute. When specifically comparing the two, the VersaCut was found to be significantly less efficient than the Piranha. This difference was even more noticeable in patients with larger prostates over 70 milliliters. Additionally, the study found that the VersaCut device was associated with a significantly higher risk of bladder mucosal injury compared to the Piranha device.

While bladder mucosal injury was the most common complication reported, it was noted to be relatively rare across all types of devices used in the study. This suggests that while some tools may perform better than others, the overall risk of major complications remains low for patients undergoing this procedure.

It is important to keep these findings in perspective. This was a meta-analysis, which combines data from multiple studies to look for patterns. While the data shows a link between certain tools and better efficiency or lower injury rates, it does not mean one tool is a guaranteed success for every patient. Individual surgical outcomes also depend on the skill of the surgeon and the specific needs of the patient.

For patients today, this research provides helpful information for discussions with their doctors. It highlights that certain technologies, such as oscillating blade systems, may offer more efficient outcomes and a better safety profile in specific cases. Patients can use this information to ask their surgical team about the specific tools they plan to use during their procedure.

What this means for you:
Some prostate surgery tools are more efficient and have fewer complications than others, especially in larger prostates.

Study Details

Study typeMeta analysis
Sample sizen = 5,980
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
OBJECTIVE: To systematically evaluate the efficiency and safety of different prostate morcellators used during prostate enucleation for benign prostatic hyperplasia (BPH). METHODS: A systematic review was performed according to the Preferred Reporting Items for Systematic Review and Meta-analyses guidelines. PubMed/Medline, Scopus, and Web of Science were searched for studies published between October 2012 and May 2025. Studies reporting clinical outcomes of morcellators used during prostate enucleation were included. Primary outcome was morcellation efficiency (g/min). Secondary outcomes included intraoperative complications, device malfunction, and cost when available. Risk of bias (RoB) was assessed using the Risk Of Bias In Non-randomised Studies of Interventions (ROBINS-I), RoB 2 tool, and European Association of Urology case-series criteria. Random-effects meta-analyses and multilevel meta-regression adjusted for prostate volume were conducted. RESULTS: A total of 22 studies comprising 5980 patients were included, most undergoing holmium laser enucleation of the prostate. The most frequently evaluated devices were the Piranha™ (Richard Wolf GmbH, Knittlingen, Germany) and Lumenis VersaCut™ (Lumenis Ltd., Yokneam, Israel; 12 and 13 studies, respectively), followed by DrillCut™ (Karl Storz SE & Co. KG, Tuttlingen, Germany), MultiCut™ (Asclepion Laser Technologies GmbH, Jena, Germany), and Cyber Blade™ (Quanta System SpA, Milan, Italy) systems. Unadjusted weighted mean morcellation efficiency was 7.80 g/min (95% confidence interval [CI] 6.26-9.34 g/min) for Piranha, 4.70 g/min (95% CI 3.61-5.79 g/min) for VersaCut, 5.90 g/min (95% CI 3.16-8.64 g/min) for DrillCut, and 9.59 g/min (95% CI 4.78-14.39 g/min) for MultiCut. In volume-adjusted meta-regression using Piranha as reference, VersaCut remained significantly less efficient (-2.75 g/min; 95% CI -4.58 to -0.92 g/min; P = 0.003), with an even greater difference in prostates >70 mL (-4.34 g/min). Bladder mucosal injury was the most frequently reported complication; however, relatively rare across all devices. Meta-analysis demonstrated a significantly higher risk with VersaCut compared to Piranha (risk ratio 3.22, 95% CI 1.81-5.71), with low heterogeneity. CONCLUSION: This systematic review provides a contemporary clinical benchmark of the efficiency and safety of currently available prostate morcellators. Oscillating blade systems, particularly the Piranha morcellator, demonstrated higher morcellation efficiency and a more favourable safety profile than reciprocating blade devices, with the largest performance differences observed in patients with larger prostates.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.